KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip.

Stephen J DiMartino, Helen Cicirello, Andrew Magyar, Simon Eng, Tina Ho, Garen Manvelian, Yamini Patel, Kauser Pervin, Ngan Trinh, Michael Fetell, Ned Braunstein, Gregory P Geba, Paula Dakin

RMD Open 12(1) e006436

PMID41545313
PMCIDPMC12815151
DOI10.1136/rmdopen-2025-006436
发表日期2026-01-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:非 KM 图;Figure 3:非 KM 图;Figure 4:非 KM 图。
摘要

摘要

BACKGROUND: Chronic pain due to osteoarthritis (OA) causes considerable burden, and current treatment options are limited. This phase III study aimed to compare the efficacy and safety of fasinumab, an investigational, anti-nerve growth factor monoclonal antibody, with placebo and naproxen in patients with moderate-to-severe pain due to OA of the knee or hip. METHODS: Patients with difficult-to-treat OA were randomised 3:3:3:1 to fasinumab 1 mg subcutaneous (SC) every 4 weeks (Q4W), fasinumab 1 mg SC every 8 weeks (Q8W), naproxen 500 mg orally two times a day or placebo. The co-primary endpoints were changes in Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain and physical function subscale scores (0-10) from baseline to week 16 for fasinumab versus placebo; comparison with naproxen was a secondary endpoint. Safety was also assessed. RESULTS: Of 3307 patients randomised, 1801 were included in the analysis for efficacy, and 3014 were included in the safety analysis. Statistically significantly greater reductions in the WOMAC pain and physical function scores, respectively, at week 16 were seen for fasinumab 1 mg Q4W (-2.90 and -2.78) compared with placebo (-2.32 and -2.10) and naproxen (-2.61 and -2.41); all p<0.005. Adjudicated arthropathies (AAs) and joint replacements occurred in all treatment groups, but were higher in the fasinumab 1 mg Q8W and 1 mg Q4W groups than in the placebo and naproxen groups. Patients with AAs: 7.2%, 9.7%, 1.1% and 2.6%, respectively; patients with joint replacements: 5.6%, 6.4%, 3.4% and 3.1%, respectively. Of the AAs in the fasinumab arms, 95.0% and 75.5% were rapid-progressive OA type 1 in the 1 mg Q8W and 1 mg Q4W arms, respectively. No new safety concerns were identified. CONCLUSION: In a difficult-to-treat population with OA, fasinumab 1 mg Q4W achieved clinically meaningful improvements by week 16 versus placebo and naproxen. The safety profile was similar to that previously observed for fasinumab. TRIAL REGISTRATION NUMBER: NCT03161093.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Study design for the main study (full analysis set). BID, two times a day; IDMC, independent data monitoring committee; Q4W, every 4 weeks; Q8W, every 8 weeks.
非 KM Figure
Figure 2Patient disposition. † 285 patients randomised to discontinued doses: 3 mg Q4W and 6 mg Q8W. FAS, full analysis set; mFAS, modified full analysis set; Q4W, every 4 weeks; Q8W, every 8 weeks.
非 KM Figure
Figure 3(A) Change from baseline in LS mean WOMAC pain subscale score and ( B ) percentage of patients achieving various levels of pain relief at week 16 (WOMAC pain subscale score, modified full analysis set). LS, least squares; Q4W, every 4 weeks; Q8W, every 8 weeks; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
非 KM Figure
Figure 4Change from baseline in weekly average walking index joint pain numerical rating scale (±SE) during year 1 (modified full analysis set). LS, least squares; Q4W, every 4 weeks; Q8W, every 8 weeks.
非 KM Figure